

5/14/2025

### Chicago Atlantic R.E.F. (REFI)

Company Update: Overweight

#### **Key Highlights:**

- Quality loan book, with >\$400Mn in principal.
- YTM IRR 17%; non-accruals only 4% of the book.
- Dividend yield of 13.3% (47c REG DPS per qtr, plus our assumption for a 12c special dividend in 4Q25).
- Loan #9 could be back to accruals later this year.
- REFI should continue to benefit from the cannabis industry's capital demand/supply imbalance.

ADE/share \$	CY24a	CY25e	CY26e	CY27e
1Q	0.54	0.47 A	0.54	0.55
2Q	0.51	0.54 E	0.55	0.56
3Q	0.57	0.54 E	0.55	0.56
4Q	0.47	0.49 E	0.49	0.51
FY	2.08	2.03 E	2.13	2.18
Reg DPS \$	CY24a	CY25e	CY26e	CY27e
1Q	0.47	0.47 A	0.47	0.47
2Q	0.47	0.47 E	0.47	0.47
3Q	0.47	0.47 E	0.47	0.47
4Q	0.47	0.47 E	0.47	0.47
FY	1.88	1.88 E	1.88	1.88
Share price (\$)		\$15.07	Rating	Overweight
Share count (mn)		20.9	Price target	No PT
Market Cap (\$Mn)		315	Fiscal Year	Dec
Ticker		REFI	Div vield	12.5%



FACTSET o min recise because type	and the		An e	May 14, 3025 in USD 8/51/1 AS
BVPS\$	CY24a	CY25e	CY26e	CY27e
1Q	14.97	14.87	14.99	15.13
2Q	14.92	14.91	15.03	15.19
3Q	14.73	14.95	15.08	15.25
4Q	14.83	14.94	15.08	15.26
Debt/Equity	CY24a	CY25e	CY26e	CY27e
1Q	28%	28%	31%	34%
2Q	26%	29%	31%	33%
3Q	18%	30%	32%	35%
4Q	34%	32%	32%	35%
YE shares (mn)	20.8	20.9	20.9	20.9
Performance		REFI	MSOS	\$&P500
30d		12%	19%	10%
90d		-5%	-22%	-3%
1yr		-4%	-71%	13%

#### **Pablo Zuanic**

ZUANIC & ASSOCIATES pablo.zuanic@zuanicgroup.com 420Odysseus; www.zuanicassociates.com



### **Company Update**

We rate REFI Overweight. Management expects net book growth for 2025 (after a seq drop in 1Q25), despite a more cautious outlook on the cannabis industry. It expects to refinance the bulk of loans maturing this year (close to 35% of the book). Per our math, based on the quality of the book, and robust spreads, the 47c regular dividend is well protected. We model a 12c special dividend for 4Q25 (vs. 18c in 4Q24 and 29c in 4Q23), which implies a 13.3% dividend yield (12.5% on the regular dividend). The stock trades at par.

#### 1Q25 recap.

- Book: Loans held for investment at carrying value amounted to \$399.5Mn at the end of March (\$396.2Mn net of CECL provisions), with \$401.5Mn in principal. New fundings in 1Q amounted to \$4.4Mn (compared with \$85Mn in 4Q24 and \$161Mn for all of 2024) and there were \$9.2Mn in repayments; PIK interest was \$1.6Mn. In terms of real estate collateral coverage, 49% of the loan book had real estate collateral coverage of less than 1x (65% below 1.25x) compared with 66% at YE24, 30% YE23 and 19% YE22. The % of the book with risk ratings of 1-2 was 60% in 4Q24 (1:6%; 2: 54%) vs. 72% at YE24. There are two loans in category 4 risk (it does not disclose which exactly), for a total of ~\$22Mn. It downgraded loans from category 2 to 3 (3 increased seq to \$137Mn from \$78Mn) due to the slower than expected growth in OH.
- Leverage: At the end of March, REFI had \$49Mn in notes payable and the revolving loan balance was at \$38Mn (credit line of \$110Mn), down from \$55Mn in Dec. Net debt was \$77Mn (\$10Mn cash balance). In terms of leverage, gross debt to equity was 28% (25% net debt/equity). The revolving facility carries rate of prime plus a range of 0%-1.25% (prime is at 7.50%), with a prime rate floor of 3.25%; with the book gross portfolio yield at 16.9%, this makes for a >900bp spread at present.
- Earnings power: ADE per fully diluted share in 1Q25 was 46c, in line with 4Q24. Net interest income (NII) was down 7% qoq to \$13Mn, on a mostly stable share count (+0.3% qoq). But 4Q24 net interest income of \$14.1Mn included \$1.9Mn of prepayment fees and other fee income, while these were only \$0.4Mn in 1Q25. In other words, NII ex non-recurring fees was slightly up seq to \$12.6Mn from \$12.3Mn, despite the drop in book size. Recurring cash opex ex management fees (and ex provisions for CECL and other non-cash items) as % of net interest income was 11.2% in 1Q25 vs. 12.7% in 4Q24. Management and incentive fees were 13.3% of net interest income, in line with 1Q24.
- **Dividend:** At 47c, the current regular dividend per share has been stable since 2Q22. The regular cash dividend in 1Q25 was 101% of ADE per basic share vs. 90% on average for CY24. Factoring the special dividend (paid in 4Q), in CY24 REFI paid out 99% of ADE per basic share (94% in CY23 and 100% in CY22).



#### More color on the loan book.

- Past dues and non-accruals: \$16.4Mn is in non-accruals (past due more than 90 days); this
  (loan #9) represented 4.1% of the book's principal at the end of March. The loan relates
  to an operator in PA (25K sq ft plus three dispensary licenses), which is in the process of
  foreclosure. At this point, it remains unclear whether the PA legislature will finally agree
  on a rec program.
- Reserves and collateral coverage: Current expected credit loss (CECL) reserve is \$3.4Mn, or 0.8% of the book. The implied real estate collateral coverage at YE24 was 1.1x.
- Loan concentration: REFI disclosed a total of 30 loans outstanding as of Mar 2025. In terms of the carrying value balance, nine loans accounted for 5% or more of the book (loan #18 in OH was 11.3% of the book; and there were four loans accounting for 6-7% of the book each; see appendix), and for 53% on a combined basis.
- Regional concentration: The REFI portfolio was spread across 16 states as of Mar'25, with six states accounting for 8% or more of the book (OH 15%; IL 15%; FL 10.5%; PA 9%; MI 8%, MO 8%), or for two thirds of the book combined. We realize operator quality will vary even within a same state market, but if we define higher risks markets based on below average wholesale prices and subpar retailer economics (rev/store; spreads), we calculate only 22% of the book is in what we deem markets with challenging economics (31% if we include PA).

#### Outlook and forward comments.

- Management expects net portfolio growth for CY25 (despite the seq drop in 1Q25), even
  though it recognizes there is generally less capex activity among operators (at least in the
  current reg context, but this could change, both at the state and federal level), and REFI
  itself has a more cautious outlook on the industry.
- Expect fundings to ramp in 2Q and 3Q vs. the 1Q pace. But not all the \$19.8Mn unfunded commitments will be necessarily deployed in 2Q and 3Q.
- Ex loans already paid or refinanced, maturities this year amount to \$140Mn, or 35% of the book. We assume most of these loans will be refinanced, with few actual exits.
- Per management, the rate outlook remains unclear, but it has generally negotiated higher floors in the event rates drop.
- Loan #9 (\$16.6Mn), in PA, has been restructured (now at 9% cash), and could be moved back to "accruals" in the future (it still showed in non-accruals in 1Q25).
- Exposure to higher risk states has been consistently reduced.



- REFI will not go above 50% leverage, or \$200Mn. Compared with current total debt of \$90Mn, this still leaves room to fund growth (or \$110Mn). To put this in context, the net book has grown by ~\$30Mn per annum over the past two years.
- Total annual dividend will remain in the 90-100% payout ratio (of ADE per basic share). We model for a special dividend for 4Q25 of 12c (implying 98% full year payout).

**Stock performance and valuation.** REFI is down 5% in the last 90 days (+12% last 30d) vs. -22% for the MSOS ETF (+19%) and -34% for direct peer AFCG (+20%). Over the last 3 months, the 10yr Treasury rate has fluctuated between 4.2% and 4.8% (4.47% now). At \$15.07, REFI trades at a 1% premium to BVPS (AFCG -37%) and the dividend yield (47c x 4) is 12.5% (16%). While other finco stocks in the cannabis space may seem more attractively valued, and growth for the group (and for REFI) has generally slowed, REFI has executed better and manages a better-quality loan book. Even without factoring a special dividend for 4Q25 (in 4Q24 this was 18c and 29c in 4Q23), per our estimates for the next nine months, the regular dividend is well protected (8pt above 10-year Treasuries).

**Table 1: MJ Lenders Valuation Comps** 

	14-May-25				
	US\$ price	BVPS	Disc Prm	Regular DPS	Dividend Yield
MJ Finco	Stocks				
AFCG	\$5.70	\$9.02	-37%	\$0.23	16.1%
IIPR	\$55.47	\$68.38	-19%	\$1.90	13.7%
LIEN	\$9.90	\$13.20	-25%	\$0.34	13.7%
NLCP	\$14.44	\$19.19	-25%	\$0.43	11.9%
REFI	\$15.07	\$14.87	1%	\$0.47	12.5%

Z&A Total Gross Net Debt Pref Stock Mkt Cap Debt to Equity & Min Int 155 22.3 0.3 129 148.5 122.2 -13% 201 1,758 28.3 0.3 1,588 297.9 151.2 -8% 1,937 23.6 201 22.7 225 0.0 23.9 8% 300 294 20.5 0.2 300 7.6 19.9 3% 394 6.9 399 322 21.0 0.4 87.2 9.9 -25% 312

Source: FactSet, company reports, Z&A estimates



Table 2: Stocks mentioned in this report

Company name	Ticker	Ticker	Rating
US MSOs			
4Front Ventures		FENTE	not rated
Ascend Wellness		AAWH	will cover
AYR Wellness		AYRWF	not rated
Cannabist		CCHWF	not rated
Cansortium		CNTMF	not rated
Cresco Labs		CRLBF	Overweight
Curaleaf Holdings		CURLF	will cover
GlassHouse Brands		GLASF	not rated
Gold Flora		GRAM	Overweight
Green Thumb Industries		GTBIF	Overweight
Grown Rogue		GRUSE	not rated
Jushi Holdings		JUSHF	Overweight
MariMed		MRMD	Overweight
Planet 13 Holdings		PLNHF	Overweight
Schwazze		SHWZ	not rated
TerrAscend		TSNDF	will cover
TILT Holdings		TLLTF	Neutral
Trulieve Cannabis		TCNNF	will cover
Verano Holdings		VRNOF	Overweight
Vext Science, Inc.		VEXTF	Overweight
Vireo Growth		VREOF	will cover
Finance (MJ) Companies			
AFC Gamma		AFCG	Overweight
Chicago Atlantic BDC		LIEN	will cover
Chicago Atlantic REAF		REFI	Overweight
Innovative Industrial Pro	perties	IIPR	will cover
New Lake Capital Partner	s	NLCP	Overweight
SHF Holdings		SHFS	not rated

Company name	Ticker	Rating
Canada LPs		
Aurora Cannabis	ACB	Neutral
Auxty Cannabis Group	CBWTF	not rated
Avant Brands	AVTBF	not rated
Avicanna	AVCN	not rated
Ayurcann Holdings	AYURF	not rated
Cannara Biotech	LOVFF	not rated
Canopy Growth Corporation	CGC	will cover
Cronos Group	CRON	not rated
Decibel Cannabis Co	DBCCF	Overweight
Organigram Holdings	OGI	not rated
Rubicon Organics	ROMJF	will cover
SNDL	SNDL	not rated
Tilray Brands	TLRY	Neutral
Village Farms Intl	VFF	Overweight
Other		
Agrify	AGFY	not rated
Cannapresso	TBD	not rated
Cantourage AG	HIGH:FF	not rated
Flora Growth	FLGC	not rated
Grow Generation	GRWG	not rated
Intercure	INCR	not rated
Is pire Technology	ISPR	will cover
Leafly	LFLY	not rated
LFTD Partners Inc.	LIFD	Overweight
Smoore International	SMORF	will cover
Springbig	SBIG	not rated
Urban-gro	UGRO	not rated
WM Technology	MAPS	Neutral

Source: Z&A ratings



# **Appendix I: Company Financials**



**Exhibit 1: Financial Highlights** 

	Dec	Dec	Mar	Jun	Sep	Dec	Dec	Mar	Jun	Sep	Dec	Dec	Dec	Dec
US\$ 000s	CY22	CY23	1Q24	2Q24	3Q24	4Q24	CY24	1Q25	2Q25e	3Q25e	4Q25e	CY25e	CY26e	CY27e
Net interest	48,858	57,147	13,240	13,183	14,459	14,068	54,951	13,042	14,708	14,733	14,825	57,308	60,505	61,900
qoq ch %	na	na	-11%	0%	10%	-3%	na	-7%	13%	0%	1%	na	na	na
yoy ch %	na	17%	-11%	-4%	5%	-5%	-4%	-1%	12%	2%	5%	4%	6%	2%
guidance														
consensus								13,813	14,004	14,259	14,368	56,464	55,950	0
Profit metrics														
Expenses	-16,565	-18,617	-4,506	-3,999	-3,248	-5,984	-17,737	-3,001	-4,080	-4,102	-5,155	-16,338	-18,484	-18,806
as % of inv inc		-33%	-34%	-30%	-22%	-43%	-32%	-23%	-28%	-28%	-35%	-29%	-31%	-30%
Income from ops	32,292	38,530	8,733	9,184	11,212	8,085	37,214	10,041	10,628	10,631	9,670	40,970	42,020	43,094
as % of inv inc		67%	66%	70%	78%	57%	68%	77%	72%	72%	65%	71%	69%	70%
consensus								9,583	9,630	9,765	9,617	38,594	39,564	0
EPS														
EPS	1.82	2.11	0.47	0.46	0.56	0.39	1.88	0.47	0.51	0.51	0.46	1.95	2.01	2.06
consensus						0.51	2.07	0.52	0.53	0.54	0.52	2.11	2.13	0.00
DPS - regular	1.81	1.88	0.47	0.47	0.47	0.47	1.88	0.47	0.47	0.47	0.47	1.88	1.88	1.88
consensus								0.48	0.48	0.48	0.56	1.99	2.03	0.00
FD Distributable earnings/share (DEPS)	2.09	2.27	0.53	0.49	0.56	0.46	2.03	0.46	0.54	0.54	0.49	2.02	2.13	2.18
Div coverage (DEPS/DPS)	116%	121%	112%	105%	118%	98%	108%	97%	114%	114%	105%	108%	113%	116%
BS & CF highlights														
Equity	264,033	271,853	285,961	292,725	295,467	308,958	308,958	310,780	311,588	312,398	312,248	312,248	314,988	318,802
Net cash (debt)	-52,284	-58,102	-74,346	-69,679	-47,240	-77,696	-77,696	-77,277	-81,187	-84,373	-88,547	-88,547	-90,245	-100,691
cash	5,716	7,898	6,904	7.071	6,760	26,400	26,400	9,879	10,000	10,000	10,000	10,000	10,000	10,000
gross debt	58,000	66,000	81,250	76,750	54,000	104,096	104,096	87,156	91,187	94,373	98,547	98,547	100,245	110,691
debt to equity	22%	24%	28%	26%	18%	34%	34%	28%	29%	30%	32%	32%	32%	35%
NAV per share	14.86	14.94	14.97	14.92	14.73	14.83	14.83	14.87	14.91	14.95	14.94	14.94	15.08	15.26
consensus								15.09	15.11	15.29	15.15	15.15	0.00	0.00
NAV per share inc cum. DPS								15.34	15.85	16.36	16.82	16.82	18.84	20.90
future cumulative DPS								0.47	0.94	1.41	1.88	1.88	3.76	5.64



**Exhibit 2: Income Statement** 

US\$ 000s	-	CV22		2024	2024		-		2025-	2025-	4005	GUAT -	cuac-	cwa.
NCOME STATEMENT	CY22	CY23	1Q24	2Q24	3Q24	4Q24	CY24	1Q25	2Q25e	3Q25e	4Q25e	CY25e	CY26e	CY27
Revenues	48,858	57,147	13,240	13,183	14,459	14,068	54,951	13,042	14,708	14,733	14,825	57,308	60,505	61,900
(+) Interest income	51,472	62,900	15,344	15,022	16,259	15,479	62,104	15,107	16,492	16,588	16,754	64,942	68,365	70,450
(-) Interest expense	-2,614	-5,753	-2,104	-1,839	-1,799	-1,411	-7,153	-2,065	-1,783	-1,856	-1,929	-7,634	-7,860	-8,550
(+) Fee and reimbursables														
Expenses	-16,565	-18,617	-4,506	-3,999	-3,248	-5,984	-17,737	-3,001	-4,080	-4,102	-5,155	-16,338	-18,484	-18,800
(-) Management and incentive fees, net	-6,562	-8,783	-1,755	-1,775	-1,669	-2,863	-8,062	-1,736	-1,801	-1,819	-2,857	-8,212	-9,045	-9,336
(-) General and administrative expenses	-3,528	-5,260	-1,390	-1,255	-1,254	-1,490	-5,389	-1,196	-1,353	-1,355	-1,364	-5,269	-5,627	-5,571
(-) Professional fees	-2,152	-2,154	-450	-409	-469	-483	-1,811	-493	-485	-486	-489	-1,954	-1,997	-2,043
(-) Stock-based compensation	-436	-1,480	-531	-836	-846	-846	-3,059	-649	-441	-442	-445	-1,977	-1,815	-1,857
(-) Organizational expense	0	0	0	0	0	0	0	0	0	0	0	0	0	(
(-) Provisions for current expected credit los:	-3,887	-940	-380	275	990	-301	583	1,073	0	0	0	1,073	0	(
Income from operations	32,292	38,530	8,733	9,184	11,212	8,085	37,214	10,041	10,628	10,631	9,670	40,970	42,020	43,094
(+) Interest income	0	76	-76	0	0	-165	-241	0	0	0	0	0	0	
(-) Interest expense	0	105	72	0	0	0	72	0	0	0	0	0	0	(
(-) Other	0	0	0	0	0	0	0	0	0	0	0	0	0	(
Profit before tax	32,292	38,710	8,730	9,184	11,212	7,920	37,045	10,041	10,628	10,631	9,670	40,970	42,020	43,094
(-) Income tax provision expense	0	0	0	0	0	0	0	0	0	0	0	0	0	(
Net Income	32,292	38,710	8,730	9,184	11,212	7,920	37,045	10,041	10,628	10,631	9,670	40,970	42,020	43,094
(-) preferred stock dividends	0	0	0	0	0	0	0	0	0	0	0	0	0	(
(-) non-controlled/non-affiliate investments	0	0	0	0	0	0	0	0	0	0	0	0	0	(
Net income attributable to common stockho	32,292	38,710	8,730	9,184	11,212	7,920	37,045	10,041	10,628	10,631	9,670	40,970	42,020	43,094
Basic EPS	1.83	2.14	0.48	0.47	0.57	0.40	1.92	0.48	0.51	0.51	0,46	1.96	2.01	2,06
FD EPS	1.82	2.11	0.47	0.46	0.56	0.39	1.88	0.47	0.51	0.51	0.46	1.95	2.01	2.0€
basic share count (Mn)	17.7	18.1	18.3	19.4	19.6	19.8	19.3	20.9	20.9	20.9	20.9	20.9	20.9	20.9
diluted share count (Mn)	17.7	18.3	18.6	19.9	20.1	20.3	19.7	21.3	20.9	20.9	20.9	21.0	20.9	20.9



**Exhibit 3: Adj Distributable Earnings** 

US\$ 000s														
INCOME STATEMENT	CY22	CY23	1Q24	2Q24	3Q24	4Q24	CY24	1Q25	2Q25e	3Q25e	4Q25e	CY25e	CY26e	CY27e
Net income	32,292	38,710	8,730	9,184	11,212	7,920	37,045	10,041	10,628	10,631	9,670	40,970	42,020	43,094
Adjustments to net income														
non-cash equity compensation expense	436	1,480	531	836	846	846	3,059	649	441	442	445	1,977	1,815	1,857
depreciation and amortization	563	551	91	92	92	-17	257	110	150	150	150	560	600	600
provision for current expected credit loss	3,887	940	380	-275	-990	301	-583	-1,073	0	0	0	-1,073	0	0
change in unrealized (gain) on debt securi	0	-76	0	0	0	165	241	0	0	0	0	0	0	0
Distributable earnings	37,179	41,606	9,808	9,837	11,159	9,214	40,094	9,728	11,219	11,223	10,265	42,434	44,436	45,551
Adjustments to distributable earnings	-1	0	0	0	0	0	0	0	0	0	0	0	0	0
Adj distributable earnings	37,178	41,606	9,808	9,837	11,159	9,214	40,094	9,728	11,219	11,223	10,265	42,434	44,436	45,551
Basic - per share	2.11	2.30	0.54	0.51	0.57	0.47	2.08	0.47	0.54	0.54	0.49	2.03	2.13	2.18
Diluted - per share	2.09	2.27	0.53	0.49	0.56	0.46	2.03	0.46	0.54	0.54	0.49	2.02	2.13	2.18
Regular cash dividend	1.81	1.88	0.47	0.47	0.47	0.47	1.88	0.47	0.47	0.47	0.47	1.88	1.88	1.88
Reg DPS / ADE fully diluted per share	86%	83%	89%	95%	84%	102%	93%	103%	88%	88%	96%	93%	88%	86%
End of period share count (mn)	17.8	18.2	19.1	19.6	20.1	20.8	20.8	20.9	20.9	20.9	20.9	20.9	20.9	20.9
Avg FD share count for the period (mn)	17.7	18.3	18.6	19.9	20.1	20.3	19.7	21.3	20.9	20.9	20.9	21.0	20.9	20.9



**Exhibit 4: Cash Flow** 

US\$ 000s														
SUMMARY CASH FLOW	CY22	CY23	1Q24	2Q24	3Q24	4Q24	CY24	1Q25	2Q25e	3Q25e	4Q25e	CY25e	CY26e	CY27
Net income	32,292	38,710	8,730	9,184	11,212	7,920	37,045	10,041	10,628	10,631	9,670	40,970	42,020	43,09
(+) adjustments ex PIK	2,012	-193	528	283	-1	1,204	1,203	-684	0	0	0	-684	0	(
(-) paid-in-kind interest	-6,920	-9,458	-3,009	-2,793	-1,886	-1,460	-9,148	-1,595	0	0	0	-1,595	0	(
(+) changes in assets and liabilities	-10,379	-643	669	-463	-594	-5,554	-5,942	-137	-38,877	5	18	-38,992	81	74
(+) other	0	0	0	0	0	0	0	0	38,121	0	0	38,121	5,335	(
Net cash provided in operating activities	17,005	28,416	6,918	6,211	8,731	2,111	23,159	7,625	9,871	10,635	9,688	37,820	47,437	43,169
(-) net uses	-125,244	-1,925	-18,717	-2,855	23,541	-41,265	-39,297	5,507	-3,962	-4,001	-4,041	-6,497	-9,855	-14٫334
Net cash used in investing activities	-125,244	-1,925	-18,717	-2,855	23,541	-41,265	-39,297	5,507	-3,962	-4,001	-4,041	-6,497	-9,855	-14,334
(-) debt	58,000	82,000	15,250	-4,500	-22,750	1,000	-11,000	-17,000	4,031	3,186	4,174	-5,609	1,699	10,446
(-) dividends	-28,174	-39,134	-13,867	-9,240	-9,258	-9,268	-41,632	-13,605	-9,820	-9,820	-9,820	-43,065	-39,280	-39,280
(+) share issuance (repurchase)	4,506	7,222	9,812	10,941	44	18,795	39,592	1,033	0	0	0	1,033	0	(
(+) other	-626	-397	-390	-390	-90	-351	-1,220	-82	0	0	0	-82	0	(
(-) stock options/warrants	0	0	0	0	0	0	0	0	0	0	0	0	0	(
Net cash provided from financing activities	33,706	49,691	10,806	-3,189	-32,054	10,177	-14,261	-29,654	-5,789	-6,634	-5,647	-47,723	-37,582	-28,834
Increase in cash and cash equivalents	-74,533	2,182	-994	167	-310	19,640	18,502	-16,521	121	0	0	-16,400	0	(
Cash at start of year	80,249	5,716	7,898	6,904	7,071	6,760	7,898	26,400	9,879	10,000	10,000	26,400	10,000	10,000
Cash at end of year	5,716	7,898	6,904	7,071	6,760	26,400	26,400	9,879	10,000	10,000	10,000	10,000	10,000	10,000
Net (debt) cash	-52,284	-58,102	-74,346	-69,679	-47,240	-77,696	-77,696	-77,277	-81,187	-84,373	-88,547	-88,547	-90,245	-100,691
Cash	5,716	7,898	6,904	7,071	6,760	26,400	26,400	9,879	10,000	10,000	10,000	10,000	10,000	10,000
D <i>e</i> bt	58,000	66,000	81,250	76,750	54,000	104,096	104,096	87,156	91,187	94,373	98,547	98,547	100,245	110,691
Debt ratios														
debt / equity	22%	24%	28%	26%	18%	34%	34%	28%	29%	30%	32%	32%	32%	359
net debt / equity	20%	21%	26%	24%	16%	25%	25%	25%	26%	27%	28%	28%	29%	329



**Exhibit 5: Balance Sheet** 

US\$000s														
BALANCE SHEET	CY22	CY23	1Q24	2Q24	3Q24	4Q24	CY24	1Q25	2Q25e	3Q25e	4Q25e	CY25e	CY26e	CY27e
Loans held for investment at carrying value,	335,333	348,668	370,488	376,782	350,582	398,130	398,130	396,181	400,143	404,145	408,186	408,186	418,041	432,376
(+) Loans held for investment	339,274	353,641	375,844	381,863	354,673	402,477	402,477	399,455	403,450	407,485	411,559	411,559	421,496	435,949
not related	0	337,238	359,317	365,460	338,270	364,239	364,239	360,988	0	0	0	0	0	0
related party	0	16,402	16,527	16,402	16,402	38,238	38,238	38,468	0	0	0	0	0	0
<ul><li>(-) Current expected credit loss reserve</li></ul>	-3,941	-4,973	-5,356	-5,081	-4,091	-4,347	-4,347	-3,274	-3,307	-3,340	-3,373	-3,373	-3,455	-3,573
Loans at fair value - related party	0	0	0	0	0	5,335	5,335	5,335	5,335	5,335	5,335	5,335	0	0
Cash and cash equivalents	5,716	7,898	6,904	7,071	6,760	26,400	26,400	9,879	10,000	10,000	10,000	10,000	10,000	10,000
Interest receivable	1,204	1,004	927	1,170	484	1,454	1,454	1,516	1,710	1,712	1,723	1,723	1,771	1,816
Other receivables and assets, net	1,018	706	5,143	629	615	459	459	525	592	593	597	597	614	629
Related party receivables	0	107	192	839	1,472	3,370	3,370	1,229	1,386	1,388	1,397	1,397	1,436	1,471
Other assets	0	0	0	0	6,000	0	0	0	0	0	0	0	0	0
Debt securities at fair value	0	842	0	0	0	0	0	0	0	0	0	0	0	0
TOTAL ASSETS	343,271	359,226	383,655	386,490	365,913	435,149	435,149	414,665	419,166	423,173	427,238	427,238	431,862	446,292
Revolving loan	58,000	66,000	81,250	76,750	54,000	55,000	55,000	38,000	42,031	45,217	49,391	49,391	51,090	61,536
Dividend payable	13,619	13,867	9,007	9,257	9,268	13,605	13,605	9,820	9,820	9,820	9,820	9,820	9,820	9,820
Management and incentives fees payable	3,296	3,244	1,755	1,775	1,669	2,863	2,863	1,736	1,300	1,302	1,310	1,310	1,347	1,380
Related party payables	1,398	2,052	1,819	1,950	1,571	2,043	2,043	1,587	1,789	1,792	1,803	1,803	1,854	1,900
Accounts payable and other liabilities	1,058	1,135	1,343	1,542	1,358	2,285	2,285	2,540	2,864	2,869	2,887	2,887	2,968	3,042
Interest reserve	1,868	1,075	2,520	2,492	2,581	1,298	1,298	548	617	619	622	622	640	656
Other liabilities	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Payable for investment purchase	0	0	0	0	0	0	0	500	0	0	0	0	0	0
Notes payable, net	0	0	0	0	0	49,096	49,096	49,156	49,156	49,156	49,156	49,156	49,156	49,156
Other	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total liabilities	79,238	87,372	97,694	93,765	70,446	126,191	126,191	103,885	107,578	110,775	114,990	114,990	116,874	127,489
Preferred stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Common stock	177	182	191	196	196	208	208	209	209	209	209	209	209	209
Additional paid in capital	268,996	277,483	291,859	298,923	299,722	318,887	318,887	320,487	320,487	320,487	320,487	320,487	320,487	320,487
Accumulated deficit	-5,140	-5,812	-6,089	394ر6-	-4,452	-10,137	-10,137	-9,916	-9,108	-8,297	-8,448	-8,448	-5,707	-1,894
Total stockholders equity	264,033	271,853	285,961	292,725	295,467	308,958	308,958	310,780	311,588	312,398	312,248	312,248	314,988	318,802
Non controlling interest	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TOTAL LIABILITIES AND EQUITY	343,271	359,226	383,655	386,490	365,913	435,149	435,149	414,665	419,166	423,173	427,238	427,238	431,862	446,292
Total net assets	264,033	271.853	285.961	292.725	295.467	308.958	308.958	310,780	311.588	312.398	312,248	312,248	314.988	318,802
NET ASSET VALUE PER SHARE	14.86	14.94	14.97	14.92	14.73	14.83	14.83	14.87	14.91	14.95	14.94	14.94	15.08	15.26
runs running granding in the order to the second	17100	A-7 (W-7)	17101	1704	A-744-J	47100	1700	A-107	17001	14100	A-710-7	A7W7	13.00	15.20



Exhibit 6: Market Size Projections (cannabis sales by state)

																	rec
US\$ Mn	CY19	CY20	CY21	CY22	CY23	CY24e	1Q25e	2Q25e	3Q25e	4Q25e	CY25e	CY26e	CY27e	CY28e	CY29e	CY30e	began
Total (med/rec)	11,665	18,035	23,993	25,200	28,053	29,831	7,664	7,931	8,002	7,990	31,587	34,185	36,382	38,448	41,201	44,074	
AZ	841	801	1,359	1,426	1,419	1,251	316	304	279	300	1,200	1,202	1,224	1,246	1,269	1,292	Jan'21
CA	2,400	4,027	4,952	4,626	4,436	3,982	1,005	1,008	956	909	3,877	3,995	4,114	4,233	4,351	4,470	Oct'16
CO	1,748	2,191	2,229	1,769	1,529	1,375	339	330	340	299	1,309	1,284	1,298	1,311	1,324	1,338	Jan'14
CT	84	117	150	150	277	294	79	84	88	93	344	368	381	394	408	423	Jan'23
FLA	506	1,308	1,603	1,708	1,862	1,789	435	437	427	417	1,717	1,675	1,704	1,734	2,653	4,001	Jul'29
GA		0	1	16	49	109	34	34	34	34	136	156	216	355	475	530	med
IL.	251	1,035	1,776	1,907	1,960	2,008	482	502	495	511	1,990	2,015	2,040	2,066	2,092	2,119	Jan'20
MA	677	962	1,644	1,755	1,806	1,838	432	472	491	480	1,875	1,923	1,957	1,992	2,028	2,064	Nov'18
MD	252	453	551	509	787	1,141	281	304	322	328	1,235	1,376	1,483	1,577	1,639	1,664	Jul'23
ME	9	16	93	171	229	265	63	69	84	74	290	304	318	334	350	367	Oct'20
MI	289	985	1,793	2,294	3,029	3,317	808	855	869	853	3,385	3,458	3,465	3,472	3,479	3,486	Dec'19
MN	20	20	25	36	66	125	34	35	37	38	143	418	619	762	877	991	Jan'26
MO	20	21	210	390	1,338	1,461	370	387	393	399	1,549	1,687	1,840	2,008	2,193	2,396	Feb'23
MT				304	319	304	78	82	67	83	310	316	324	332	341	351	Jan '22
NH	10	13	17	20	24	27	8	8	8	8	30	34	37	40	44	47	med
NJ	95	196	217	556	800	1,046	268	280	292	304	1,143	1,252	1,373	1,506	1,652	1,813	Apr'22
NM	119	119	119	358	556	603	150	148	151	149	597	598	609	609	609	609	Apr'22
NV	702	780	1,042	882	825	828	184	184	188	180	736	740	754	769	783	798	Jul'17
NY	173	200	250	265	431	1,148	505	554	603	652	2,312	3,071	3,195	3,327	3,470	3,621	Dec'22
OH	56	223	379	467	482	675	227	260	266	274	1,026	1,376	1,700	1,773	1,848	1,928	Aug'24
OK	428	831	941	780	728	714	179	185	175	175	714	724	735	746	757	769	med
OR	840	1,111	1,184	994	955	968	236	245	252	244	978	987	997	1,007	1,017	1,028	Oct'15
PA	671	823	1,353	1,457	1,530	1,726	428	423	418	414	1,682	1,990	2,404	2,666	2,784	2,908	Jul'26
RI	40	47	44	53	108	117	30	30	31	31	123	132	142	151	161	170	Dec'22
VA	0	10	27	100	167	237	67	68	70	71	276	307	501	995	1,245	1,403	Jul'27
VT	5	6	8	9	11	12	3	3	3	3	14	15	17	19	20	22	May'22
WA	1,200	1,280	1,422	1,294	1,259	1,265	306	315	327	320	1,268	1,270	1,273	1,275	1,278	1,281	Jul'14
WV	0	0	0	22	66	85	23	24	25	26	99	116	129	129	129	129	med
Other states	229	459	603	883	1,005	1,120	295	300	312	322	1,229	1,392	1,532	1,621	1,925	2,057	



### **Appendix II: Valuation Comps**



Exhibit 7: Valuation Comps for Lenders to the Cannabis Industry (per latest disclosure – may differ from FactSet headline numbers)

		14-May-25 US\$ price	BVPS	Disc Prm	Regular DPS	Dividend Yield
MJ Finco Stocks						
Advanced Flower Capital	AFCG	\$5.70	\$9.02	-37%	\$0.23	16.1%
Innovative Industrial Properties	IIPR	\$55,47	\$68.38	-19%	\$1.90	13.7%
Chicago Atlantic BDC	LIEN	\$9.90	\$13.20	-25%	\$0.34	13.7%
NewLake Capital Partners	NLCP	\$14,44	\$19.19	-25%	\$0.43	11.9%
Chicago Atlantic Real Estate Finance	REFI	\$15.07	\$14.87	1%	\$0.47	12.5%

mn	mn	Total	Gross		Net Debt		Pref Stock
shares	deriv	Mkt Cap	Debt	Cash	to Equity	Equity	& Min Int
22.3	0.3	129	148.5	122.2	-13%	201	
28.3	0.3	1,588	297.9	151.2	-8%	1,937	23.6
22.7		225	0.0	23.9	8%	300	
20.5	0.2	300	7.6	19.9	3%	394	6.9
21.0	0.4	322	87.2	9.9	-25%	312	
	22.3 28.3 22.7 20.5	22.3 0.3 28.3 0.3 22.7 20.5 0.2	shares         deriv         Mkt Cap           22.3         0.3         129           28.3         0.3         1,588           22.7         225           20.5         0.2         300	shares         deriv         Mkt Cap         Debt           22.3         0.3         129         148.5           28.3         0.3         1,588         297.9           22.7         225         0.0           20.5         0.2         300         7.6	shares         deriv         Mkt Cap         Debt         Cash           22.3         0.3         129         148.5         122.2           28.3         0.3         1,588         297.9         151.2           22.7         225         0.0         23.9           20.5         0.2         300         7.6         19.9	shares         deriv         Mkt Cap         Debt         Cash         to Equity           22.3         0.3         129         148.5         122.2         -13%           28.3         0.3         1,588         297.9         151.2         -8%           22.7         225         0.0         23.9         8%           20.5         0.2         300         7.6         19.9         3%	shares         deriv         Mkt Cap         Debt         Cash         to Equity         Equity           22.3         0.3         129         148.5         122.2         -13%         201           28.3         0.3         1,588         297.9         151.2         -8%         1,937           22.7         225         0.0         23.9         8%         300           20.5         0.2         300         7.6         19.9         3%         394

Source: Z&A estimates



Exhibit 8: mREITs

			5/13/25				Mkt				Sto	ck Performar	ice
US\$Mn			Price	Price to	Div	(mn)	Сар	Debt to	Net	Ent	Last	Last	Last
Company name	Ticker	Listing	US\$	BVPS	Yield	Shares	US\$Mn	Equity	(Debt)	Value	30d	90d	12mo
mREITS				0.69x	14.4%						17%	-12%	-17%
Arbor Realty Trust Inc	ABR	NYSE	11.14	0.90x	15.4%	189.3	2,107	427%	-9,315	11,423	6%	-19%	-15%
Ares Commercial Real Estate Corporation	ACRE	NYSE	4.95	0.50x	18.2%	54.5	270	217%	-1,106	1,376	39%	-19%	-28%
Advanced Flower Capital Inc.	AFCG	NASDAQ	5.70	0.63x	24.0%	22.3	127	94%	-85	212	20%	-34%	-54%
Apollo Commercial Real Estate Finance,	ARI	NYSE	9.97	0.74x	11.0%	138.2	1,377	345%	-6,073	7,450	23%	0%	-1%
Blackstone Mortgage Trust, Inc. Class #	BXMT	NYSE	19.78	0.92x	10.3%	172.8	3,417	424%	-15,401	18,818	13%	4%	11%
Claros Mortgage Trust, Inc.	CMTG	NYSE	2.61	0.19x	32.6%	139.4	364	253%	-4,756	5,119	13%	-19%	-69%
Granite Point Mortgage Trust Inc.	GPMT	NYSE	2.38	0.19x	8.4%	48.8	116	242%	-1,358	1,475	30%	-22%	-35%
KKR Real Estate Finance Trust, Inc.	KREF	NYSE	9.62	0.67x	10.4%	68.7	661	494%	-4,794	5,455	12%	-13%	0%
Ladder Capital Corp. Class A	LADR	NYSE	10.75	0.91x	8.6%	127.1	1,366	210%	-1,830	3,196	9%	-9%	-4%
Chicago Atlantic Real Estate Finance, In	REFI	NASDAQ	15.07	1.01x	12.5%	20.8	314	34%	-78	392	12%	-5%	-4%
Starwood Property Trust, Inc.	STWD	NYSE	20.03	1.06x	9.6%	337.4	6,757	310%	-19,177	25,935	12%	2%	-1%
TPG RE Finance Trust, Inc.	TRTX	NYSE	00.8	0.58x	12.0%	81.0	648	232%	-2,378	3,026	18%	-7%	-7%
Cannabis "Fincos"													
Advanced Flower Capital Inc.	AFCG	NASDAQ	5.70	0.63x	24.0%	22.3	127	94%	-85	212	20%	-34%	-54%
Innovative Industrial Properties Inc	IIPR	NYSE	55.47	0.83x	13.7%	28.3	1,572	16%	-148	1,719	12%	-25%	-47%
NewLake Capital Partners, Inc.	NLCP	US OTC	14.44	0.75x	10.8%	20.5	296	2%	12	284	8%	-12%	-29%
Chicago Atlantic BDC, Inc.	LIEN	NASDAQ	9.90	0.75x	10.1%	22,8	226	0%	24	202	-8%	-15%	-12%
SHF Holdings Inc Class A	SHFS	NASDAQ	2.40	-0.54x	NA	2.8	7	-97%	-10	16	8%	-72%	-85%
Chicago Atlantic Real Estate Finance, In	REFI	NASDAQ	15.07	1.01x	12.5%	20.8	314	34%	-78	392	12%	-5%	-4%



**Exhibit 9: Industrial REITs** 

			5/13/25				Mkt				<u>Sto</u>	ck Performar	nce
US\$Mn			Price	Price to	Div	(mn)	Cap	Debt to	Net	Ent	Last	Last	Last
Company name	Ticker	Listing	US\$	BVPS	Yield	Shares	US\$Mn	Equity	(Debt)	Value	30d	90d	12mo
Industrial REITS				1.47x	5.5%						11%	-11%	-13%
Americold Realty Trust, Inc.	COLD	NYSE	17.82	1.59x	5.0%	284.3	5,064	116%	-3,633	8,697	-7%	-18%	-26%
EastGroup Properties, Inc.	EGP	NYSE	171.52	2.68x	3.2%	51.8	8,889	47%	-1,550	10,439	11%	-4%	4%
First Industrial Realty Trust, Inc.	FR	NYSE	51.11	2.54x	3.0%	132.3	6,764	84%	-2,184	8,948	12%	-9%	7%
Innovative Industrial Properties Inc	IIP'R	NYSE	55.47	0.83x	13.7%	28.3	1,572	16%	-148	1,719	12%	-25%	-47%
Industrial Logistics Properties Trust	ILPT	NASDAQ	3.18	0.39x	1.3%	66.1	210	801%	-4,077	4,287	26%	-21%	-20%
LXP Industrial Trust	LXP	NYSE	8.31	1.18x	6.4%	294.5	2,446	77%	-1,485	3,931	10%	-2%	-5%
NewLake Capital Partners, Inc.	NLCP	US OTC	14.44	0.75x	11.9%	20.5	296	2%	12	284	8%	-12%	-29%
Prologis, Inc.	PLD	NYSE	109.37	1.90x	3.6%	926.3	101,303	62%	-31,955	133,258	14%	-10%	2%
Plymouth Industrial REIT, Inc.	PLYM	NYSE	16.31	1.30x	5.9%	45.4	740	115%	-612	1,353	16%	-2%	-22%
Rexford Industrial Realty, Inc.	REXR	NYSE	35.48	0.97x	4.7%	225.3	7,993	42%	-3,449	11,442	9%	-14%	-21%
STAG Industrial, Inc.	STAG	NYSE	35.26	1.90x	4.2%	186.5	6,576	89%	-3,060	9,636	12%	0%	0%
Terreno Realty Corporation	TRNO	NYSE	58.81	1.55x	3.3%	99.2	5,836	25%	-922	6,758	8%	-12%	7%
Cannabis "Fincos"													
Advanced Flower Capital Inc.	AFCG	NASDAQ	5.70	0.63x	24.0%	22.33	127	94%	-85	212	20%	-34%	-54%
Innovative Industrial Properties Inc	IIPR	NYSE	55.47	0.83x	13.7%	28.33	1572	16%	-148	1719	12%	-25%	-47%
NewLake Capital Partners, Inc.	NLCP	US OTC	14.44	0.75x	11.9%	20.51	296	2%	12	284	8%	-12%	-29%
Chicago Atlantic BDC, Inc.	LIEN	NASDAQ	9.90	0.75x	11.9%	22,82	226	0%	24	202	-8%	-15%	-12%
SHF Holdings Inc Class A	SHFS	NASDAQ	2.40	-0.54x	0.0%	2.78	7	-97%	-10	16	8%	-72%	-85%
Chicago Atlantic Real Estate Finance, In	REFI	NASDAQ	15.07	1.01x	12.5%	20.83	314	34%	-78	392	12%	-5%	-4%



Exhibit 10: BDCs

			5/13/25				Mkt				Sto	ck Performa	nce
US\$Mn			Price	Price to	Div	(mn)	Сар	Debt to	Net	Ent	Last	Last	Last
Company name	Ticker	Listing	US\$	BVPS	Yield	Shares	US\$Mn	Equity	(Debt)	Value	30d	90d	12mo
BDCs				0.88x	13.9%			125%			3%	-12%	-13%
Gladstone Investment Corporation	GAIN	NASDAQ	14.12	1.06x	6.8%	36.7	518	82%	-395	913	7%	5%	-1%
Great Elm Capital Corp	GECC	NASDAQ	10.60	0.92x	13.4%	11.5	122	143%	-181	304	12%	0%	3%
Gladstone Capital Corporation	GLAD	NASDAQ	26.52	1.24x	7.5%	22.2	590	68%	-322	912	10%	-6%	20%
Horizon Technology Finance Corporati	HRZN	NASDAQ	7.58	1.00x	17.4%	39.9	302	155%	-367	669	-8%	-21%	-36%
Chicago Atlantic BDC, Inc.	LIEN	NASDAQ	9.90	0.75x	11.9%	22,8	226	0%	24	202	-8%	-15%	-12%
Logan Ridge Finance Corporation	LRFC	NASDAQ	17.66	0.60x	7.8%	2.7	47	132%	-73	119	-6%	-29%	-21%
Monroe Capital Corp.	MRCC	NASDAQ	6.16	0.71x	16.2%	21.7	134	156%	-283	416	-10%	-29%	-15%
OFS Capital Corp.	OFS	NASDAQ	8.63	0.72x	15.8%	13,4	116	154%	-241	356	5%	6%	-10%
Oxford Square Capital Corp.	OXSQ	NASDAQ	2.47	1.18x	17.0%	69.8	172	85%	-89	261	-2%	-12%	-23%
PennantPark Investment Corporation	PNNT	NYSE	6.86	0.91x	13.7%	65.3	448	156%	-722	1,170	11%	-4%	-6%
Portman Ridge Finance Corporation	PTMN	NASDAQ	12.45	0.66x	20.4%	9.2	115	153%	-193	307	5%	-28%	-37%
Saratoga Investment Corp.	SAR	NYSE	24.10	0.93x	12.3%	15.2	366	199%	-577	943	7%	-4%	4%
Stellus Capital Investment Corp.	SCM	NYSE	12.96	0.96x	12.3%	27.5	356	159%	-573	929	6%	-13%	-9%
TriplePoint Venture Growth BDC Corp.	TPVG	NYSE	6.62	0.77x	19.6%	40.1	266	115%	-320	586	13%	-14%	-28%
WhiteHorse Finance, Inc.	WHF	NASDAQ	9.29	0.75x	16.6%	23.2	216	124%	-326	542	3%	-13%	-27%
Cannabis "Fincos"													
Advanced Flower Capital Inc.	AFCG	NASDAQ	5.70	0.63x	24.0%	22.33	127	94%	-85	212	20%	-34%	-54%
Innovative Industrial Properties Inc	IIPR	NYSE	55.47	0.83x	13.7%	28.33	1572	16%	-148	1719	12%	-25%	-47%
NewLake Capital Partners, Inc.	NLCP	US OTC	14.44	0.75x	11.9%	20.51	296	2%	12	284	8%	-12%	-29%
Chicago Atlantic BDC, Inc.	LIEN	NASDAQ	9.90	0.75x	11.9%	22,82	226	0%	24	202	-8%	-15%	-12%
SHF Holdings Inc Class A	SHFS	NASDAQ	2.40	-0.54x	0.0%	2.78	7	-97%	-10	16	8%	-72%	-85%
Chicago Atlantic Real Estate Finance, In	REFI	NASDAQ	15.07	1.01x	12.5%	20.83	314	34%	-78	392	12%	-5%	-4%



**Exhibit 11: US MSO Valuation Multiples** 

							NET DEBT RATIOS				BROA	DER DEFIN	TION OF NET	DEBT
US\$Mn	Z8.A	Spot EV / S	ales	Z&A	Spot EV / EB	ITDA	Net Deb	ot/Sales	Net Debt	/EBITDA	BDND	/Sales	BDND/	EBITDA
14-May-25	Current	CY25e	CY26e	Current	CY25e	CY26e	Current	CY25	Current	CY25	Current	CY25	Current	CY25
US MSOs	1.4x	1.1x	0.9x	6.5x	5.4x	4.3x								
Ascend Wellness	1.1x	1.1x	1.0x	4.8x	5.0x	4.5x	-0.4x	-0.4x	-2.0x	-2.1x	-0.9x	-1.0x	-4.2x	-4.4x
Ayr Wellness	1.2x	1.2x	1.2x	7.3x	6.1x	5.6x	-0.9x	-0.9x	-5.2x	-4.3x	-1.1x	-1.2x	-6.8x	-5.7x
Cannabist Co	1.1x	1.2x	1.2x	14.5x	11.3x	8.4x	-0.7x	-0.8x	-9.5x	-7.4x	-1.0x	-1.1x	-13.5x	-10.5x
Cansortium	1.1x	na	na	3.8x	na	na	-0.6x	na	-2.0x	na	-0.9x	na	-3.2x	na
Cresco Labs	1.3x	1.3x	1.3x	5.6x	5.8x	5.2x	-0.5x	-0.5x	-2.0x	-2.1x	-0.9x	-0.9x	-3.6x	-3.7x
Curaleaf	1.5x	1.5x	1.4x	6.5x	6.9x	5.9x	-0.5x	-0.5x	-2.2x	-2.4x	-0.9x	-0.9x	-3.9x	-4.1x
4Front Ventures	2.1x	na	na	34.4x	na	na	-1.2x	na	-19.6x	na	-2.0x	na	-33.8x	na
Glass House	3.3x	3.2x	2.5x	19.7x	17.1x	11.2x	-0.1x	-0.1x	-0.6x	-0.5x	-0.3x	-0.3x	-1.8x	-1.6x
Vireo Growth (pf)	1.3x	1.2x	0.9x	5.5x	4.9x	3.1x	0.1x	na	0.5x	na	-0.6x	na	-2.1x	na
Green Thumb	1.2x	1.3x	1.2x	3.7x	4.2x	3.9x	0.0x	0.0x	-0.1x	-0.1x	-0.1x	-0.1x	-0.3x	-0.3x
Grown Rogue	1.9x	na	na	2.8x	na	na	0.2x	na	0.3x	na	0.0x	na	0.1x	na
iAnthus	1.1x	na	na	7.5x	na	na	-0.9x	na	-6.1x	na	-1.0x	na	-6.4x	na
Jushi	1.5x	1.5x	1.4x	12.4x	8.0x	6.7x	-0.6x	-0.6x	-5.3x	-3.5x	-1.2x	-1.2x	-10.3x	-6.7x
MariMed	0.9x	0.8x	0.8x	6.0x	5.9x	4.2x	-0.4x	-0.4x	-2.8x	-2.8x	-0.6x	-0.5x	-3.9x	-3.8x
Planet 13	0.8x	0.8x	0.7x	na	14.2x	5.8x	0.1x	0.1x	na	2.4x	-0.1x	-0.1x	na	-2.0x
TerrAscend	1.5x	1.5x	1.4x	7.4x	7.1x	6.2x	-0.6x	-0.6x	-2.9x	-2.7x	-1.0x	-1.1x	-5.1x	-4.9x
TILT	1.1x	na	na	51.4x	na	na	-0.6x	na	-28.6x	na	-1.1x	na	-49.9x	na
Trulieve	1.4x	1.4x	1.4x	3.8x	4.1x	4.2x	-0.2x	-0.2x	-0.6x	-0.7x	-0.7x	-0.7x	-1.8x	-2.0x
Verano	1.1x	1.1x	1.0x	3.7x	3.8x	3.6x	-0.4x	-0.4x	-1.3x	-1.4x	-0.8x	-0.8x	-2.6x	-2.7x
Vext	1.3x	1.1x	0.8x	3.9x	3.6x	1.9x	-0.8x	-0.6x	-2.4x	-2.2x	-0.8x	-0.6x	-2.4x	-2.2x

<sup>1)</sup> Current is based on the latest reported qtr annualized (Sales and EBITDA); 2) We take FactSet consensus estimates for CY25e and CY26e multiples, if available.



**Exhibit 12: Stock Performance** 

14-May-25	Sto	ck Performar	ice_
	Last	Last	Last
Ticker	30d	90d	12mo
US MSOs			
Ascend	10%	-19%	-75%
Ауг	89%	-41%	-89%
Cannabist	65%	-10%	-80%
Cansortium	-6%	-26%	-69%
Cresco	20%	-21%	-66%
Curaleaf	8%	-40%	-84%
4Front	-67%	-80%	-97%
GlassHouse	44%	6%	-34%
Gold Flora	MN/A	-30%	-85%
Grown Rogue	9%	-28%	-39%
Green Thumb	9%	-23%	-57%
iAnthus	-54%	-44%	-77%
Jushi	16%	-7%	-51%
MariMed	13%	-32%	-66%
Planet13	6%	-28%	-58%
Schwazze	na	-29%	-97%
StateHouse	na	na	-46%
Trulieve	31%	-5%	-62%
TerrAscend	48%	-39%	-77%
Verano	39%	-39%	-85%
Vext	-21%	-14%	-64%
Vireo Growth	4%	-27%	-26%
International			
InterCure	24%	-32%	-41%
PharmaCielo	-31%	4%	107%

	Sto	ck Performan	ce
	Last	Last	Last
Ticker	30d	90d	12mo
Canadian LPs			
Aurora	22%	-19%	-19%
Avant	-10%	-24%	-63%
Auxly	8%	60%	42%
Ayurcann	2%	-39%	-41%
Cannara	-1%	8%	50%
Canopy	57%	-18%	-84%
Cronos	18%	5%	-25%
Decibel	20%	-13%	-38%
Entourage	0%	25%	-58%
High Tide	13%	-15%	1%
OGI	23%	-12%	-28%
Rubicon	-22%	9%	18%
SNDL	-3%	-27%	-43%
Tilray	-6%	-51%	-76%
VFF	85%	19%	-26%
Tech			
LFLY	50%	15%	-84%
SBIG	63%	-1%	-52%
MAPS	10%	-12%	0%
Vape parts			
GNLN	-98%	-100%	-100%
ISPR	-12%	-30%	-49%
SMORF	0%	2%	34%
TLLTF	28%	-1%	-78%

		Stock Performance	
	Last	Last	Last
Ticker	30d	90d	12mo
MJ Fincos			
AFCG	20%	-34%	-54%
IIPR	13%	-25%	-47%
NLCP	8%	-12%	-29%
SHFS	8%	-72%	-85%
LIEN	-8%	-15%	-12%
REFI	12%	-5%	-4%
Pix & Shovel			
AGFY	52%	30%	559%
GRWG	23%	-24%	-63%
HYFM	24%	-41%	-64%
SMG	16%	-12%	-14%
UGRO	-30%	-47%	-78%
CBD			
CVSI	-5%	-32%	-41%
CWEB	10%	-16%	-49%
LFID	-8%	19%	-69%
Index			
S&P 500	10%	-3%	13%
S&P 477	0%	-2%	7%
Nasdaq	15%	2%	35%
MSOS ETF	19%	-22%	-71%
YOLO ETF	19%	-16%	-52%
Simple Group Aver	ages		
Large Canada LP:	33%	-17%	-50%
Tier 1 MSOs	21%	-26%	-71%

Source: FactSet



## **Appendix III: Bio and Disclaimers**



#### **Analyst Bio**

Pablo Zuanic is a well-known and highly rated equity analyst following the cannabis and psychedelics sector. Over the past five years he launched coverage of over 40 companies in the US, Canada, and overseas (MSOs, LPs, CBD, ancillary, psychedelics), kept close track of sectoral trends, and followed the reform process in the US and elsewhere. His firm Zuanic & Associates publishes equity research on the cannabis and psychedelics sectors, both from a macro/sectoral level in a thematic manner, as well as specific reports on listed stocks. The research service is aimed at institutional investors and corporations. The firm is also available for short-term consulting and research advisory projects. At various points in his career, Pablo was II ranked and called as expert witness in industry investigations. He has a deep global background having covered stocks over the past 20 years in the US, Europe, Latin America, and Asia, across consumer sub sectors. Prior employers include JP Morgan, Barings, and Cantor Fitzgerald. An MBA graduate of Harvard Business School, he started his career as a management consultant, which brings a strategic mindset to his approach to equity research. *Pablo Zuanic can be contacted via the company's portal www.zuanicassociates.com; via email pablo.zuanic@zuanicgroup.com; or via X @4200dysseus*.



#### **Disclosures and Disclaimers**

**About the firm:** Zuanic & Associates is a domestic limited liability company (LLC) registered in the state of New Jersey. The company's registered address is Five Greentree Centre, 525 Route 73, N Suite 104, Marlton, New Jersey 08053, USA. Pablo Zuanic is the registered agent. The firm publishes equity research on selected stocks in the cannabis and psychedelics sector, as well as thematic macro industry notes. The firm also provides consulting and advisory services. Potential conflicts of interest are duly reflected in the respective specific company reports.

**Analyst Certification:** The publishing analyst, whose name appears on the front page of this report, certifies that the views expressed in this independent research report accurately reflects his personal views about the subject securities or issuers discussed in this report. His opinions and estimates are based on his best judgement at the time of publication and are subject to change without notice. As per the company's policy, the author of this report does not own shares in any company he covers.

Other: This report is for use by professional and or institutional investors only, and it is deemed impersonal investment advice, published on a bona fide and regular basis. This report is for informational purposes only and is based on publicly available data believed to be reliable, but no representation is made whether such data are accurate or complete. As such, this report should not be regarded by its recipients as a substitute for obtaining independent investment advice and/or exercise of their own judgement. When making an investment decision this information should be viewed as just one factor in the investment decision process. Neither the publishing analyst, nor any of the company's officers and directors, accept any liability for any loss or damage arising out of the use of all or any part of the analyst's research.

Risks: The financial instruments mentioned in this report may not be suitable for all investors and investors must make their own investment decisions based on their specific investment objectives. Past performance should not be taken as an indication or guarantee of future performance. The price, value of and income from, any of the financial instruments featured in this report can rise as well as fall and be affected by changes in political, financial, and economic factors. If a financial instrument is denominated in a currency other than the investor's currency, a change in exchange rates may adversely affect the price or value of, or income derived from, the financial instrument, and such investors effectively assume currency risk.

**Disclosure:** Zuanic & Associates offers advisory and research services, and it also organizes investor events and conferences. The firm is often engaged by various operators in the cannabis industry (both plant touching companies and those providing services, private and public, in North America and overseas) on an ongoing or ad hoc basis. The company discussed in this report is a paying customer of the services provided by the firm.

**Copyright:** No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author.